New Drug to Alleviate Hot Flushes Available on NHS in England
The NHS in England will now provide Veoza, a non-hormonal treatment for menopausal hot flushes, to over 500,000 women.
The National Institute for Health and Care Excellence (NICE) has approved the use of Veoza, also known as fezolinetant, for women experiencing hot flushes associated with menopause. This decision marks a significant advancement in treatment options for the approximately 70% of women affected by these symptoms during menopause.
Veoza is particularly beneficial for women who cannot use hormone replacement therapy (HRT) due to various health concerns, such as a history of breast or ovarian cancer, blood clots, or high blood pressure. The drug works by blocking nerve pathways in the brain that trigger hot flushes and night sweats, providing a much-needed alternative for those seeking relief from menopausal symptoms.
Helen Knight, director of medicines evaluation at NICE, emphasized the importance of this new treatment, stating that it can significantly improve the quality of life for women who have limited options. The approval of Veoza is expected to provide relief to around 500,000 women in England, allowing them to better manage their menopausal symptoms.
Dr. Sue Mann, national clinical director in women’s health for NHS England, expressed optimism about the introduction of Veoza, highlighting its potential to empower women to take control of their health during this challenging phase of life. The drug is administered as a 45mg tablet taken once daily, offering a straightforward and effective solution for managing hot flushes.